DPX 101
Alternative Names: DPX-101Latest Information Update: 18 Mar 2026
At a glance
- Originator Damona Pharmaceuticals
- Class Antidementias; Antipsychotics; Nootropics; Small molecules
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Cognition disorders; Schizophrenia
Most Recent Events
- 18 Mar 2026 Preclinical trials in Alzheimer's disease in Canada (PO), prior to March 2026 (Damona Pharmaceuticals pipeline, March 2026)
- 18 Mar 2026 Pharmacodynamics data from a preclinical trial in Alzheimer's Disease released by Damona Pharmaceuticals (Damona Pharmaceuticals pipeline, March 2026)
- 04 Feb 2025 Updated pharmacodynamics data from a preclinical trial in Cognition disorders released by Damona Pharmaceuticals